Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Exelixis and NCI's CTEP enter CRADA to further evaluate cabozantinib

Exelixis, Inc. today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) for further evaluation of cabozantinib, Exelixis' lead compound, in a variety of solid tumors.

28 Nov 2011

Increased meat consumption positively associated with aggressive prostate cancer

Increased consumption of ground beef or processed meat is positively associated with aggressive prostate cancer, according to a study published Nov. 23 in the online journal PLoS ONE.

24 Nov 2011

Men less willing to participate in cancer screening than women

Although men have higher cancer mortality rates than women, they are less willing to be screened for cancer, according to a study conducted by researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues at Sanoa Consulting LLC, Muscle Shoals, Ala., and the New York University College of Dentistry.

23 Nov 2011

Medicare to cover infusion costs for prostate cancer vaccine, company says

In Medicare news, the drug maker Dendreon says federal officials have said they will pay doctors to administer the drug. Also, policymakers are studying Medigap to see if curbs on those policies could help cut Medicare costs.

23 Nov 2011

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer.

23 Nov 2011

IsoRay receives Washington State approval for GliaSite system to treat brain cancer

IsoRay, Inc. announced today it has received final approval from the State of Washington Department of Health to manufacture its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer. In conjunction with the previously announced FDA clearance, the Washington State approval represents IsoRay's final regulatory hurdle to commence the sale of its GliaSite brain cancer treatment in the United States.

22 Nov 2011

Scientists design math model that could guide future prostate cancer treatments

Scientists have designed a first draft of a mathematical model that someday could guide treatment decisions for advanced prostate cancer, in part by helping doctors predict how individual patients will respond to therapy based on the biology of their tumors.

22 Nov 2011

Multi-center cabozantinib trial for hormone receptor-positive breast cancer with bone metastases initiated

Exelixis, Inc. today announced the initiation of an investigator-sponsored trial of cabozantinib in women with hormone receptor-positive breast cancer with bone metastases.

21 Nov 2011

Two genetic rearrangements may trigger 5 to 7% of breast cancers

Researchers at the University of Michigan Comprehensive Cancer Center have discovered two cancer-spurring gene rearrangements that may trigger 5 to 7 percent of all breast cancers.

20 Nov 2011

FDA approves EUSA's orphan drug ERWINAZE for acute lymphoblastic leukemia

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that the US Food and Drug Administration (FDA) has approved its orphan drug ERWINAZE (asparaginase Erwinia chrysanthemi) for the treatment of acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to E. coli-derived asparaginase.

19 Nov 2011

LGBT seniors face higher rates of disability, physical and mental distress

Aging and health issues facing lesbian, gay, bisexual and transgender baby boomers have been largely ignored by services, policies and research. These seniors face higher rates of disability, physical and mental distress and a lack of access to services, according to the first study on aging and health in these communities.

17 Nov 2011

VHIO, MGHCC sign tumor biomarker agreement

The President of the BBVA Foundation, Francisco Gonz-lez, Jose Baselga, Chief of Hematology/Oncology at Massachusetts General Hospital Cancer Center (MGHCC), and Andr-s de Kelety, Managing Director at the Vall d'Hebr-n Institute of Oncology (VHIO) in Barcelona, yesterday signed the agreement creating the BBVA Foundation Tumor Biomarkers Research Program.

17 Nov 2011

Aurora kinase inhibitor may treat neuroendocrine prostate cancer

An international team of researchers led by clinicians at Weill Cornell Medical College have discovered a genetic Achilles' heel in an aggressive type of prostate cancer -- a vulnerability they say can be attacked by a targeted drug that is already in clinical trials to treat other types of cancers.

17 Nov 2011

New treatment may be on the horizon for neuroendocrine prostate cancers

A recent report in Cancer Discovery, a journal of the American Association for Cancer Research, suggests that a new treatment may be on the horizon for neuroendocrine prostate cancers, the most lethal subtype of this disease.

17 Nov 2011

MDxHealth total revenues decrease 7% for third quarter 2011

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, today issued its business update for the third quarter and for the nine months ended September 30, 2011.

17 Nov 2011

Multivitamin use linked to less healthy behaviors

The lack of evidence on multivitamin health benefits is no impediment to their widespread popularity, with over half the U.S. population popping such pills. This translates into a $27 billion industry, which lures consumers with the illusory promise of better health. But shocking new research suggests taking multivitamins might have the opposite effect -- not simply on the metabolic level, but on a metaphysical one: promoting a false sense of invulnerability that actually leads users to engage in riskier behaviors.

17 Nov 2011

New 2-DG-ABT combination cancer therapy triggers apoptosis

Researchers at the University of California, San Diego School of Medicine and Kyushu University Medical School say a novel combination of a specific sugar molecule with a pair of cell-killing drugs prompts a wide variety of cancer cell types to kill themselves, a process called apoptosis or programmed cell death.

17 Nov 2011

SHARPIN protein regulates human cell activity

The research teams headed by Prof. Johanna Ivaska (University of Turku and VTT Technical Research Centre of Finland) and Prof. Marko Salmi (University of Turku and the National Institute for Health and Welfare) have discovered that the SHARPIN protein regulates human cell activity.

17 Nov 2011

ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today new preclinical data from two separate studies of darinaparsin, a novel organic arsenic, in various solid tumor models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

16 Nov 2011

Amgen's XGEVA delays onset of bone metastases in men with prostate cancer

Amgen announced today the publication of results from a Phase 3 trial (the '147 study) that evaluated XGEVA (denosumab) for use in preventing or delaying the onset of bone metastases in men with nonmetastatic castration-resistant prostate cancer.

16 Nov 2011